logo
American Critical Minerals Announces Appointment of Agapito Associates, LLC, to Define a National Instrument 43-101 Exploration Target for Lithium at its Green River Project

American Critical Minerals Announces Appointment of Agapito Associates, LLC, to Define a National Instrument 43-101 Exploration Target for Lithium at its Green River Project

VANCOUVER, BC / ACCESS Newswire American Critical Minerals Corp. (' American Critical Minerals ' or the ' Company ') (CSE:KCLI)(OTCQB:APCOF)(Frankfurt:2P3) is pleased to announce that it has engaged Agapito Associates, LLC (' Agapito ' or ' Agapito Associates '), to define a National Instrument 43-101 (' NI 43-101 ') Exploration Target for Lithium at the Company's Green River Project. Agapito will also update the Company's existing Technical Report prepared by them and effective September 12, 2012. Such report was focused on the Potash potential of the Green River Project and included a 43-101 Exploration Target for Potash. However, given the emergence of the lithium brines in the Paradox Basin as a major potential source of lithium and the speed and success of development on neighboring projects, it makes sense to now include lithium as a key focus for the Company. Agapito's work is expected to be completed early in the fourth quarter of 2025. The Company will release the results as received.
Management Commentary
Simon Clarke President & CEO stated, 'we are excited to expand our NI 43-101 Technical Report to encompass the large-scale lithium potential across our Project. This has been showcased in recent years by a number of players, but particularly Anson Resources which has a Project contiguous to the North of our Green River Project and a Project adjacent to the South. Anson has advanced both its Projects materially and recently announced a successful Pilot with Koch Technology and an MOU to develop a DLE Demonstration Plant at Green River with POSCO Holdings.
Historic oil and gas drill logs highlight that the same lithium brines are present across our Project Area with similar grades and potential and the advanced development work undertaken by Anson also helps de-risk our Project which is sandwiched between the two Anson Projects. American Critical Minerals is in a unique position as our Project contains both large scale Potash and Lithium targets for what we see as brown-field development moving forward.'
Agapito will carry out a comprehensive set of tasks to evaluate the potential size, grade, and economic viability of lithium-bearing deposits at the Green River Potash and Lithium Project. This work will include a detailed review of existing geological, geophysical, and geochemical data, along with hydrogeological studies focused on the lithium brine target layers-specifically assessing aquifer permeability, storability, and water chemistry. The evaluation will also involve resource modeling and preliminary economic assessments to help refine exploration targets and prioritize areas for further investigation. As part of this effort, Agapito will estimate the brine tonnage and lithium concentration for each of the identified lithium-bearing layers.
About Agapito Associates, LLC
Agapito Associates is partnered with Tiberius Energy Services (' Tiberius ') and Lane Power & Energy Solutions (' Lane ') to form E3 Partners, LLC (' E3 ')-a unified team that brings together deep professional expertise and hands-on contracting capabilities. Through this strategic alliance, Agapito now offers a fully integrated approach to well management, combining Agapito's decades of geotechnical and subsurface engineering experience with Tiberius's strength in well services and project coordination, and Lane's proven track record in complex underground construction. As E3, Agapito has the resources and expertise to successfully manage, drill, and abandon each well with efficiency, safety, and regulatory compliance, ensuring every phase of the project is executed to the highest standard.
About American Critical Minerals' Green River Potash and Lithium Project
The Green River Potash and Lithium Project is situated within Utah's highly productive Paradox Basin, located 20 miles northwest of Moab, Utah and has significant logistical advantages including close proximity to major rail hubs, airport, roads, water, towns and labour markets. It also benefits from close proximity to the agricultural and industrial heartland of America and numerous potential end-users for its products.
The history of oil and gas production across the Paradox Basin provides geologic data from historic wells across the Project, and the wider Basin, validating and de-risking the potential for high grade potash and large amounts of contained lithium. Wells in and around the project reported lithium up to 500 ppm, bromine up to 6,100 ppm and boron up to 1,260 ppm (Gilbride & Santos, 2012). This data is reinforced by nearby potash production and the advanced stage of neighbouring lithium projects. The Paradox Basin is believed to contain up to 56 billion tonnes of lithium brines, potentially the largest such resource in US (Source: Anson Fastmarkets Presentation – https://wcsecure.weblink.com.au/pdf/ASN/02823465.pdf) The Company also has a 43-101 Exploration Target of 600 million to 1 billion tonnes of sylvinite (the most important source for the production of potash in North America) with average grades ranging from 19% to 29% KCL.**
The Company holds a 100% interest in eleven State of Utah (' SITLA ') mineral and minerals salt leases covering approximately 7,050 acres, 1,094 federal lithium brine claims (BLM Placer Claims) covering 21,150 acres, and 11 federal (BLM) potash prospecting permits covering approximately 25,480 acres. Through these leases, permits and claims the Company has the ability to explore for potash, lithium and potential by-products across the entire Green River Project (approx. 32,530 acres). The Company is authorized to drill a total of 7 exploratory drill holes across the Project (pending bonding the recently approved 4 drill holes).
Intrepid Potash, Inc. is America's largest potash company and only U.S. domestic potash producer and currently produces potash from its nearby Moab Solution Mine, which the Company believes provides strong evidence of stratigraphic continuity within this part of the Paradox Basin (www.intrepidpotash.com). Anson Resources Ltd. has advanced lithium development projects contiguous to the northern boundary of our Green River Project and neighbouring to the south. Anson has a large initial resource, robust definitive feasibility study and has recently completed successful piloting operations through its partnership with Koch Technology Solutions, as well as an offtake agreement with LG Energy Solution. The Anson exploration targets encompass the combined Mississippian Leadville Formation and the Pennsylvanian Paradox Formation brine-bearing clastic layers, which also underlie American Critical Minerals' entire project area (www.ansonresources.com)*.
In 2022, the U.S. imported approx. 96.5% of its annual potash requirements with domestic producers receiving a higher sales price due to proximity to market (intrepidpotash.com/ August 15, 2024, Investor Presentation). In March 2024, the US Senate introduced a bill to include key fertilizers and potash on the US Department of Interior list of Critical Minerals which already includes lithium. Recent market estimates suggest that the global potash market is over US$50 billion annually and growing at a compound annual growth rate ('CAGR') of close to 5%. Annual lithium demand is now estimated to be over 1 million tonnes globally and continuing to grow rapidly.***
Qualified Person
The Technical content of this news release has been reviewed and approved by Dean Besserer, P.Geo., the Chief Operations Officer (' COO ') of the Company and a qualified person for the purposes of NI 43-101.
On behalf of the Board of Directors
Simon Clarke, President & CEO
Contact: (604)-551-9665
* American Critical Minerals' management cautions that results or discoveries on properties in proximity to the American Critical Minerals' properties may not necessarily be indicative of the presence of mineralization on the Company's properties.
** A report titled 'NI 43-101 Technical Report – Green River Potash Project, Grand County, Utah, USA', prepared by Agapito Associates Inc., and dated effective September 12, 2012, quantifies the Green River Potash Project's potash exploration potential in the form of a NI 43-101 Exploration Target. The Exploration Target estimate was prepared in accordance with the National Instrument 43-101 -Standards of Disclosure for Mineral Projects (' NI 43-101 '). It should be noted that Exploration Targets are conceptual in nature and there has been insufficient exploration to define them as Mineral Resources, and, while reasonable potential may exist, it is uncertain whether further exploration will result in the determination of a Mineral Resource under NI 43-101. The Exploration Target stated in the Agapito Report is not being reported as part of any Mineral Resource or Mineral Reserve. A copy of the report can be accessed on the corporate website for the Company: www.acmineralscorp.com.
***United States Geological Survey, Mineral Commodity Summaries, January 2024 (https://pubs.usgs.gov/periodicals/mcs2024/mcs2024-potash.pdf).
Cautionary Statements Regarding Forward Looking Information
This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading 'Risks and Uncertainties' in the Company's most recently filed MD&A. The Company does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding future confirmation drilling and its intended outcomes. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by the Company in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and information.
SOURCE: American Critical Minerals Corp.
The post American Critical Minerals Announces Appointment of Agapito Associates, LLC, to Define a National Instrument 43-101 Exploration Target for Lithium at its Green River Project appeared first on DA80 Hub.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position

Business Wire

time2 hours ago

  • Business Wire

OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: "To date, it remains impossible to raise funds on Euronext for a biotechnology company that needs to conduct clinical proof-of-concept trials. As a result, our hopes for revenue and therefore cash availability rest primarily on discussions with potential buyers of our assets. The various cost-cutting measures we have taken since the beginning of this year are enabling us to continue these discussions over time, and the last quarter will be crucial in this regard." Karine LIGNEL, Managing Director and COO of Oncodesign Precision Medicine adds: "In a very difficult financial environment, we have taken management decisions that have enabled us to significantly reduce our expenses and thus extend our cash flow horizon as much as possible. We have also set up an equity financing line to deal with market uncertainties. Nevertheless, the situation remains complicated, and we are making every effort to secure a partnership for one of our assets." Key financial data A cost reduction program was implemented in the first half of 2025: Negotiations were held with the banks and BPI that granted the loan, resulting in a six-month deferral of principal repayments starting in April 2025 Expenses were reduced through The layoff of five employees in early 2025 A 50% reduction in the compensation of non-salaried corporate officers A freeze on salaries and bonus payments for the 2024 fiscal year A reduction in spending on non-priority programs. In terms of cash flow, rather than from an accounting perspective, this results in a reduction in payroll costs of €242k in the first half of 2025 and a projected reduction of €440k in the second half of this year. The reduction in expenditure is particularly significant for the item 'subcontracting and fees,' which will fall from €2,900k in the first half of 2024 to €1,773k in the first half of 2025. R&D expenses amounted to €1.74 million in the first half of 2025, compared with €3.61 million in the same period last year, as the company focused its efforts on the clinical development of OPM-101. Reintegration, in close collaboration with Servier, of all OPM-201 data and product stocks The most significant financial item in the first half of 2025 is the reintegration, as provided for in the partnership agreement, of the stock of OPM-201 GMP material produced by Servier. As this reintegration is being carried out without financial competing, OPM has called upon an external expert to determine fair value for these stocks. This expert carried out three different valuations to arrive at this fair value. A summary of these valuations is shown in the table below: The expert concluded that the fair value of these inventories falls within a range of €13 million to €16.2 million. OPM used the lower end of this range. OPM's revenue for the first half of 2025 was €0.1 million, the same as in the first half of 2024. Other income mainly consists of subsidies amounting to €0.3 million and €0.3 million in provision reversals. OPM's financial result was (€0.26) million, compared with (€0.1) million in the same period last year, mainly due to interest on outstanding loans and financial income from cash investments. OPM recorded €0.4 million in R&D tax credits in the first half of 2025, down 52% compared to last year. The amount of R&D tax credits was reduced by the amount of public aid, the R&D expenditure base decreased, and the rules for collecting R&D tax credits changed (exclusion of technology watch patents, etc.). OPM's half-year net income thus stands at €9,846k, due to the integration of OPM-201 inventories at an estimated value of €13m. Cash position of €2.5m at June 30, 2025 As of June 30, 2025, OPM had cash reserves of €2.5 million, before receiving the Research Tax Credit, compared to €9.6 million (including the Research Tax Credit) as of June 30, 2024. The Research Tax Credit, amounting to €1.1 million, was received in July 2025. OPM has access to a maximum €5 million equity financing facility, which it has not yet used. The Company is in discussions with financial and pharmaceutical partners with the goal of signing a partnership agreement or raising funds. 2025 perspectives OPM has submitted its Phase 1b/2a protocol for the REVERT study evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 and is awaiting a response from Swiss ethics institutions. The first patient is expected to be enrolled by the end of 2025. Work on radioligands is continuing as part of the COMETE project. Partnership prospects or transfer mainly focus on the two most advanced molecules to date (OPM-101 and OPM-201). OPM's goal is to license or transfer OPM-101 at the end of Phase 2a to a pharmaceutical partner who will complete its development and commercialization. While we do not anticipate licensing or sales before the end of this phase in 2027, we are considering the possibility of a pharmaceutical partner taking a licensing option with the payment of an exclusivity fee, giving them first refusal on the results. For OPM-201, the objective is to find a partnership similar to the one we found with Servier in 2019 or a buyer. Availability of the 2025 half-year financial report The 2025 half-year financial report will be available on the company's website, within the legal deadline, before October 31, 2025. About Oncodesign Precision Medicine (OPM) Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers. OPM currently has two kinase inhibitors in clinical phase: OPM-101, intended for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, has demonstrated a significant therapeutic margin and absence of toxicity in its phase I healthy volunteers, with the start of phase 1b/2a in Oncology scheduled for early 2025. OPM-201, initially licensed to Servier and intended for the treatment of Parkinson's disease, completed its phase I trial in healthy volunteers at the end of 2024, and was reintegrated into OPM's portfolio. Both molecules come from the Nanocyclix ® technology platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. We now have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase. OPM's other two technology platforms are: OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, on which we have a partnership with Servier for the search for targets in pancreatic cancer, PROMETHE ® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, on which we are currently discussing partnerships with vectorization manufacturers. OPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in Dijon, at the heart of the university and hospital cluster, and employs 14 people. More info at: Forward-looking statements This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be identified by the use of words such as, without limitation, "believes", "anticipates", "expects", "projects", "plans", "seeks", "estimates", "may", "will" and "continue" and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable when they were made but which may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company's control. Consequently, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, the forward-looking statements, forecasts and estimates speak only as of the date of publication of this document. The Company disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which these statements, forecasts or estimates are based, except as required by French law.

WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.
WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.

Hamilton Spectator

time3 hours ago

  • Hamilton Spectator

WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.

Vancouver, B.C., July 31, 2025 (GLOBE NEWSWIRE) — WestKam Gold Corp. (the 'Company' or 'WestKam') is pleased to announce that field crews are being mobilized to commence a prospecting and soil sampling program on the Company's 100%-owned Will Project, located on Mt. Williams near Goldbridge, British Columbia. The Will Project encompasses 1,142.47 hectares of highly prospective terrain and is in good standing through January 30, 2027. The 2025 exploration campaign will focus on a zone of listwanite alteration in the upper reaches of Mt. Williams, an area with geological characteristics conducive to gold and antimony mineralization. The targeted alteration zone is situated on trend with the Minto-Olympic shear zone, currently being advanced by Endurance Gold Corp., and is interpreted to share a similar structural and lithological setting. Listwanite-hosted orogenic systems are globally recognized for their association with significant gold deposits. Antimony is commonly associated in such settings—particularly in structurally controlled quartz-carbonate veining in proximity to ultramafic rocks. The program will include systematic soil sampling, geological mapping and prospecting, aimed at delineating geochemical anomalies and identifying potential drill targets within the target area shown on Figure #1. Peter Laipnieks, President commented: 'We are excited to initiate more work on the Will Project, which represents a compelling opportunity for discovery. The combination of listwanite alteration, favorable structural setting, and the potential for both gold and antimony mineralization positions this property as a high-priority exploration target for WestKam.' WestKam remains committed to responsible exploration practices and ongoing collaboration with local communities and stakeholders as operations advance on Mt. Williams. Figure # 1 – Will Property Area with Proposed Soil Grid Area Please click to view image Qualified Person Lorne Warner, P. Geo, is a qualifies qualified person as defined by National Instrument 43-101 and has reviewed and approved the scientific and technical disclosure in this news release. About WestKam WestKam Gold Corp. is focused on acquiring and developing mineral properties, with strong potential to host significant resources, in Western Canada . We are looking for additional projects that are in an established mining district with highly prospective geology that could host significant resources. ON BEHALF OF THE BOARD OF DIRECTORS 'Peter Laipnieks' Peter Laipnieks, President & CEO Contacts: WestKam Gold Corp. Suite 900, 570 Granville Street Vancouver, BC V6C 3P1 Contact: Investor Relations: 250.216.5671 Email: westkam007@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-looking information All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. In particular, this news release contains forward-looking information regarding the timing of completing and filing of the Interim Filings. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Group Eleven Closes C$5.75M Bought Deal Private Placement, Including Full Exercise of C$750,000 Underwriters' Option
Group Eleven Closes C$5.75M Bought Deal Private Placement, Including Full Exercise of C$750,000 Underwriters' Option

Yahoo

time5 hours ago

  • Yahoo

Group Eleven Closes C$5.75M Bought Deal Private Placement, Including Full Exercise of C$750,000 Underwriters' Option

Vancouver, British Columbia--(Newsfile Corp. - July 31, 2025) - Group Eleven Resources Corp. (TSXV: ZNG) (OTCQB: GRLVF) (FSE: 3GE) (the "Company") is pleased to announce the closing of its previously-announced "bought deal" private placement for aggregate gross proceeds of C$5,750,000 (the "Offering") through the issuance of 17,968,750 common shares of the Company (the "Common Shares") at a price of C$0.32 per Common Share. The Offering was completed pursuant to an underwriting agreement between the Company, and Cormark Securities Inc. and Beacon Securities Limited (together, the "Underwriters") and included the full exercise of the Underwriters' option. The Company intends to use the net proceeds from the Offering to expand the remaining funded exploration drill program at Ballywire from approximately 5,000m to approximately 25,000m, and for working capital and general corporate purposes. The Common Shares were offered and sold in Canada pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "LIFE exemption") and pursuant to the accredited investor exemption under section 2.3 of NI 45-106 (the "Accredited Investor exemption"). The Common Shares were also offered and sold in certain jurisdictions outside of Canada where there would be no prospectus filing or comparable obligation, ongoing reporting requirement or requisite regulatory or governmental approval in such jurisdictions. The Common Shares issued under the Offering to Canadian purchasers (other than in the province of Québec) and offshore purchasers pursuant to the LIFE exemption are not subject to a hold period, subject to the hold period imposed by the TSX Venture Exchange for an insider purchaser described below. The Common Shares issued under the Offering pursuant to the Accredited Investor exemption are subject to a hold period of four months and one day. In connection with the Offering, the Company paid the Underwriters an aggregate cash commission of C$314,550 and issued to the Underwriters an aggregate of 887,812 compensation warrants (the "Compensation Warrants"). Each Compensation Warrant is exercisable to acquire one Common Share at a price of C$0.32 until July 31, 2027, subject to adjustment in certain events. The Compensation Warrants are subject to a hold period of four months and one day. Glencore Canada Corporation ("Glencore") did not exercise its participation right, which was triggered by the Offering. Following completion of the Offering, Glencore holds an approximate 14.1% ownership interest in the Company. A director of the Company (the "Insider") acquired 156,250 Common Shares pursuant to the Offering. Participation by the Insider in the Offering was a "related party transaction" within the meaning of that term in Multilateral Instrument 61-101 - Protection of Minority Shareholders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the formal valuation requirement set out in section 5.5(a) and the minority approval requirement set out in section 5.7(1)(a) of MI 61-101 on the basis that, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Offering, insofar as it involved interested parties, exceeded 25% of the Company's market capitalization. The Company did not file a material change report at least 21 days in advance of the closing of the Offering as the participation of the Insider in the Offering had not been confirmed at that time. The Common Shares issued to the Insider are subject to a hold period of four months under the policies of the TSX Venture Exchange. Qualified Person Technical information in this news release has been approved by Professor Garth Earls, Eur Geol, FSEG, geological consultant at IGS (International Geoscience Services) Limited, an independent 'Qualified Person' as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. About Group Eleven Resources Group Eleven Resources Corp. (TSXV: ZNG) (OTCQB: GRLVF) and (FSE: 3GE) is drilling the most significant mineral discovery in the Republic of Ireland in over a decade. The Company announced the Ballywire discovery in September 2022, demonstrating high grades of zinc, lead, silver, copper, germanium and locally, antimony. Key intercepts to date include: 10.8m of 10.0% Zn+Pb and 109 g/t Ag (G11-468-03) 10.1m of 8.6% Zn+Pb and 46 g/t Ag (G11-468-06) 10.5m of 14.7% Zn+Pb, 399 g/t Ag and 0.31% Cu (G11-468-12) 11.2m of 8.9% Zn+Pb and 83 g/t Ag (G11-3552-03) 29.6m of 10.6% Zn+Pb, 78 g/t Ag and 0.15% Cu (G11-3552-12) 11.8m of 11.6% Zn+Pb, 48 g/t Ag (G11-3552-18) 15.6m of 11.6% Zn+Pb, 122 g/t Ag and 0.19% Cu (G11-3552-27) 12.0m of 1.4% Zn+Pb, 560 g/t Ag, 2.30% Cu and 0.17% Sb (25-3552-31), including 6.4m of 2.1% Zn+Pb, 838 g/t Ag, 3.72% Cu and 0.27% Sb (25-3552-31) 39.7m of 9.5% Zn+Pb, 131 g/t Ag and 0.27% Cu (25-3552-35) Ballywire is located 20km from Company's 77.64%-owned Stonepark zinc-lead deposit1, which itself is located adjacent to Glencore's Pallas Green zinc-lead deposit2. The Company's two largest shareholders are Michael Gentile (15.3%) and Glencore Canada Corporation (15.2% interest). Additional information about the Company is available at ON BEHALF OF THE BOARD OF DIRECTORSBart Jaworski, Chief Executive Officer E: | T: +353-85-833-2463 E: | T: 604-781-4915 Cautionary Note Regarding Forward-Looking Information This press release contains forward-looking information ("forward-looking statements") within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding the use of proceeds from the Offering, the future results of operations, performance and achievements of the Company, including the Company drilling the most significant mineral discovery in the Republic of Ireland in over a decade. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, variations in the nature, quality and quantity of any mineral deposits that may be located. All of the Company's public disclosure filings may be accessed via and readers are urged to review these materials, including the technical reports filed with respect to the Company's mineral properties. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 1 Stonepark MRE is 5.1 million tonnes of 11.3% Zn+Pb (8.7% Zn and 2.6% Pb), Inferred (Apr-17-2018)2 Pallas Green MRE is 45.4 million tonnes of 8.4% Zn+Pb (7.2% Zn + 1.2% Pb), Inferred (Glencore, Dec-31-2024) Not for distribution to U.S. news wire services or dissemination in the United States To view the source version of this press release, please visit Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store